E A Mistry1, A M Mistry2, T Mehta3, N Arora4, A K Starosciak5, F D L R La Rosa5, J E Siegler6, S E Kasner6, R Chitale2, M Fusco2, M Froehler7, S Yaghi8, M Schrag9, P Khatri. 1. From the Departments of Neurology (E.A.M., M.S.) and eva.a.mistry@vumc.org. 2. Neurosurgery (A.M.M., R.C., M. Fusco), and. 3. Department of Neurology and Neurosurgery (T.M.), University of Minnesota, Minneapolis, Minnesota. 4. Department of Neurology (N.A.), University of Missouri, Columbia, Missouri. 5. Baptist Health Neuroscience Center (A.K.S., F.D.L.R.L.R.), Miami, Florida. 6. Department of Neurology (J.E.S., S.E.K.), University of Pennsylvania, Philadelphia, Pennsylvania. 7. Cerebrovascular Program (M. Froehler), Vanderbilt University Medical Center, Nashville, Tennessee. 8. New York University Langone Health (S.Y.), Brooklyn, New York. 9. From the Departments of Neurology (E.A.M., M.S.) and.
Abstract
BACKGROUND AND PURPOSE: The increased severity of white matter disease is associated with worse outcomes and an increased rate of intracerebral hemorrhage in patients with ischemic stroke undergoing thrombolytic treatment. However, whether white matter disease is associated with outcomes in patients undergoing endovascular treatment remains unclear. MATERIALS AND METHODS: In this prespecified exploratory analysis of our prospective multi-institutional study that enrolled consecutive adult patients with anterior circulation ischemic stroke undergoing endovascular treatment from November 2017 to September 2018, we compared the following outcomes between patients with none-to-minimal (van Swieten score, 0-2) and moderate-to-severe (van Swieten score, 3-4) white matter disease using logistic regression: 90-day mRS 3-6, death, intracerebral hemorrhage, successful recanalization, and early neurologic recovery. RESULTS: Of the 485 patients enrolled in the Blood Pressure after Endovascular Stroke Therapy (BEST) study, 389 had white matter disease graded (50% women; median age, 68 years; range, 58-79 years). A van Swieten score of 3-4 (n = 74/389, 19%) was associated with a higher rate of 90-day mRS of 3-6 (45% versus 18%; adjusted OR, 2.73; 95% CI, 1.34-5.93; P = .008). Although the death rate was higher in patients with van Swieten scores of 3-4 (26% versus 15%), the adjusted likelihood was not significantly different (adjusted OR, 1.14; 95% CI, 0.56-2.26; P = .710). Ordered regression revealed a shift toward worse mRS scores with increasing van Swieten scores (adjusted common OR, 3.04; 95% CI, 1.93-4.84; P < .001). No associations between white matter disease severity and intracerebral hemorrhage, successful recanalization, and early neurologic recovery were observed. CONCLUSIONS: Moderate-to-severe white matter disease is associated with worse outcomes in patients undergoing endovascular treatment without a significant increase in hemorrhagic complications. Studies comparing patients with and without endovascular treatment are necessary to determine whether the benefit of endovascular treatment is attenuated with greater white matter disease.
BACKGROUND AND PURPOSE: The increased severity of white matter disease is associated with worse outcomes and an increased rate of intracerebral hemorrhage in patients with ischemic stroke undergoing thrombolytic treatment. However, whether white matter disease is associated with outcomes in patients undergoing endovascular treatment remains unclear. MATERIALS AND METHODS: In this prespecified exploratory analysis of our prospective multi-institutional study that enrolled consecutive adult patients with anterior circulation ischemic stroke undergoing endovascular treatment from November 2017 to September 2018, we compared the following outcomes between patients with none-to-minimal (van Swieten score, 0-2) and moderate-to-severe (van Swieten score, 3-4) white matter disease using logistic regression: 90-day mRS 3-6, death, intracerebral hemorrhage, successful recanalization, and early neurologic recovery. RESULTS: Of the 485 patients enrolled in the Blood Pressure after Endovascular Stroke Therapy (BEST) study, 389 had white matter disease graded (50% women; median age, 68 years; range, 58-79 years). A van Swieten score of 3-4 (n = 74/389, 19%) was associated with a higher rate of 90-day mRS of 3-6 (45% versus 18%; adjusted OR, 2.73; 95% CI, 1.34-5.93; P = .008). Although the death rate was higher in patients with van Swieten scores of 3-4 (26% versus 15%), the adjusted likelihood was not significantly different (adjusted OR, 1.14; 95% CI, 0.56-2.26; P = .710). Ordered regression revealed a shift toward worse mRS scores with increasing van Swieten scores (adjusted common OR, 3.04; 95% CI, 1.93-4.84; P < .001). No associations between white matter disease severity and intracerebral hemorrhage, successful recanalization, and early neurologic recovery were observed. CONCLUSIONS: Moderate-to-severe white matter disease is associated with worse outcomes in patients undergoing endovascular treatment without a significant increase in hemorrhagic complications. Studies comparing patients with and without endovascular treatment are necessary to determine whether the benefit of endovascular treatment is attenuated with greater white matter disease.
Authors: Gregory W Albers; Michael P Marks; Stephanie Kemp; Soren Christensen; Jenny P Tsai; Santiago Ortega-Gutierrez; Ryan A McTaggart; Michel T Torbey; May Kim-Tenser; Thabele Leslie-Mazwi; Amrou Sarraj; Scott E Kasner; Sameer A Ansari; Sharon D Yeatts; Scott Hamilton; Michael Mlynash; Jeremy J Heit; Greg Zaharchuk; Sun Kim; Janice Carrozzella; Yuko Y Palesch; Andrew M Demchuk; Roland Bammer; Philip W Lavori; Joseph P Broderick; Maarten G Lansberg Journal: N Engl J Med Date: 2018-01-24 Impact factor: 91.245
Authors: Simon Nagel; Mehdi Bouslama; Lars U Krause; Clemens Küpper; Mirko Messer; Martina Petersen; Stephan Lowens; Moritz Herzberg; Peter A Ringleb; Markus A Möhlenbruch; Steffen Tiedt; Fabricio O Lima; Diogo C Haussen; Wade S Smith; Michael H Lev; Raul G Nogueira Journal: Stroke Date: 2018-10 Impact factor: 7.914
Authors: Eva A Mistry; Heidi Sucharew; Akshitkumar M Mistry; Tapan Mehta; Niraj Arora; Amy K Starosciak; Felipe De Los Rios La Rosa; James Ernest Siegler; Natasha R Barnhill; Kishan Patel; Salman Assad; Amjad Tarboosh; Katarina Dakay; Sanjana Salwi; Aurora S Cruz; Jeffrey Wagner; Enzo Fortuny; Alicia Bennett; Robert F James; Bharathi Jagadeesan; Christopher Streib; Kristine O'Phelan; Scott E Kasner; Stewart A Weber; Rohan Chitale; John J Volpi; Stephan Mayer; Shadi Yaghi; Mahesh V Jayaraman; Pooja Khatri Journal: Stroke Date: 2019-10-07 Impact factor: 7.914
Authors: Eric E Smith; Jeffrey L Saver; Margueritte Cox; Li Liang; Roland Matsouaka; Ying Xian; Deepak L Bhatt; Gregg C Fonarow; Lee H Schwamm Journal: Circulation Date: 2017-10-05 Impact factor: 29.690
Authors: Katie E Osborn; Jonathan M Alverio; Logan Dumitrescu; Kimberly R Pechman; Katherine A Gifford; Timothy J Hohman; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Zhong-Song Shi; Yince Loh; David S Liebeskind; Jeffrey L Saver; Nestor R Gonzalez; Satoshi Tateshima; Reza Jahan; Lei Feng; Paul M Vespa; Sidney Starkman; Noriko Salamon; J Pablo Villablance; Latisha K Ali; Bruce Ovbiagele; Doojin Kim; Fernando Viñuela; Gary R Duckwiler Journal: Stroke Date: 2012-05-10 Impact factor: 7.914